Vitamin K2 drops could shield breastfed infants from bleeding risk

NCT ID NCT07620236

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether giving vitamin K2 (MK-7) supplements to breastfed infants or their breastfeeding mothers can prevent vitamin K deficiency at 2 months of age. About 134 healthy, full-term babies who received standard vitamin K shots at birth will be enrolled. Some infants will get MK-7 drops, others a placebo, and some mothers will take MK-7 capsules. The goal is to see if extra vitamin K2 improves blood markers of vitamin K status and reduces the risk of rare but serious bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Vitamin K2 (menaquinone-7; MK-7) drops or capsules, with or without vitamin D3

What this could lead to

If it works, this could point toward a simple daily supplement to prevent vitamin K deficiency and related bleeding in breastfed babies.

What could go wrong

This is an early, small study (134 infants) that has not yet started recruiting. It may not show a clear benefit, and results may not apply to all infants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFANT VITAMIN K STATUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Breast Feeding hemorrhagic disease of newborn vitamin K deficiency hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••